Olaparib with or without bevacizumab for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.
- Your tumor has a BRCA gene change or a high level of a DNA repair deficiency called HRD.
- You have already had surgery to remove as much cancer as possible and completed at least 4 cycles of platinum-based chemotherapy.
- Your cancer has not grown during or right after your first chemotherapy treatment.
- You have not taken a PARP inhibitor before (like olaparib, niraparib, or rucaparib).
- You are 18 or older and are in generally good health (able to do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
This trial tests a combination of three drugs (olaparib, durvalumab, and bevacizumab) given before surgery for women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if this treatment shrinks the cancer enough to allow successful surgery.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
Hear when a new Fallopian Tube Endometrioid Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.